The type II transmembrane multidomain serine proteinase MT-SP1/matriptase is highly expressed in many human cancer-derived cell lines and has been implicated in extracellular matrix re-modeling, tumor growth, and metastasis. We have expressed the catalytic domain of MT-SP1 and solved the crystal structures of complexes with benzamidine at 1.3 Å and bovine pancreatic trypsin inhibitor at 2.9 Å. MT-SP1 exhibits a trypsinlike serine proteinase fold, featuring a unique nine-residue 60-insertion loop that influences interactions with protein substrates. The structure discloses a trypsinlike S1 pocket, a small hydrophobic S2 subsite, and an open negatively charged S4 cavity that favors the binding of basic P3/P4 residues. A complementary charge pattern on the surface opposite the active site cleft suggests a distinct docking of the preceding low density lipoprotein receptor class A domain. The benzamidine crystals possess a freely accessible active site and are hence well suited for soaking small molecules, facilitating the improvement of inhibitors. The crystal structure of the MT-SP1 complex with bovine pancreatic trypsin inhibitor serves as a model for hepatocyte growth factor activator inhibitor 1, the physiological inhibitor of MT-SP1, and suggests determinants for the substrate specificity.The activity of proteolytic enzymes is required at multiple stages during the growth, invasion, and progression of human tumors (for a review, see Ref. 1). For example, these complex processes entail extensive re-modeling of the extracellular matrix as well as the activation of latent growth factors and pro-angiogenic proteins. Consequently, the high level expression of particular proteinases often correlates with poor patient survival for several different cancers (see, for instance, Ref. The enzyme was initially assigned as a gelatinase, because of its gelatinolytic properties and gelatinase-like molecular weight. However, isolation and sequencing of the cDNA revealed a 683-residue multidomain proteinase with a C-terminal serine proteinase domain. The enzyme was then named matriptase to emphasize its matrix degrading properties and trypsin-like specificity (5). Independently, Takeuchi and coworkers (6) cloned and characterized a type-II membranebound trypsin-like serine proteinase from a human prostatic cancer cell line, which they called membrane-type serine proteinase 1, MT-SP1. This 855-residue proteinase contained two tandem repeats of the complement component C1r/s domain (CUB, derived from complement factor/1R-urchin embryonic growth factor/bone morphogenetic protein) and four tandem repeats of the low density lipoprotein receptor (LDLR) class A domain between the N-terminal transmembrane signal anchor and the C-terminal catalytic domain (5, 6). Because the matriptase sequence reported by Lin turned out to be part of the translated MT-SP1 cDNA sequence, matriptase is likely to be a form of MT-SP1 produced by ectodomain shedding (7). Alternatively, the two cDNAs may result from alternative splicing. MT-SP1 is highly exp...